Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 8/20 | 0.60 |
| ▸ | MAOA | P21397 | 3/20 | 0.55 |
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | MYC | P01106 | 1/20 | 0.47 |
| ▸ | MAX | P61244 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792516 | 1.00 | MAPK1 (0.60) | MAPK1MAOAMAOBALDH1A1DNM1 | |
| SCHEMBL7486836 | 0.87 | CISD1 (0.62) | MAOAALDH1A1MYCMAXMAPT | |
| SCHEMBL7486833 | 0.87 | CISD1 (0.62) | MAOAALDH1A1MYCMAXMAPT | |
| SCHEMBL6785812 | 0.86 | ALDH1A1 (0.48) | MAPK1MAOAMAOBALDH1A1DNM1 | |
| SCHEMBL6785809 | 0.86 | ALDH1A1 (0.48) | MAPK1MAOAMAOBALDH1A1DNM1 | |
| SCHEMBL7489759 | 0.86 | FFAR1 (0.64) | MAPK1MAOAALDH1A1MCHR1MYC | |
| SCHEMBL7489754 | 0.86 | FFAR1 (0.64) | MAPK1MAOAALDH1A1MCHR1MYC | |
| SCHEMBL6791768 | 0.85 | PTPN12 (0.60) | ALDH1A1MAPT | |
| SCHEMBL7484741 | 0.85 | PTPN12 (0.60) | ALDH1A1MAPT | |
| SCHEMBL6791775 | 0.85 | PTPN12 (0.60) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040197268-A1 | Method of imaging amyloid deposits using substituted rhodanine derivatives | AUGELLI-SZAFRAN CORINNE ELIZAB (US) | 2004-10-07 | — | — | US | disclosed |
| EP-1192144-A1 | RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS | WARNER-LAMBERT COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000076988-A1 | RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040197268-A1 | Method of imaging amyloid deposits using substituted rhodanine derivatives | APP, PSEN1, PSEN2 | MAPK1 1314/4885MAOA 239/4885MAOB 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.